{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T10:55:29Z","timestamp":1790679329851,"version":"4.1.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2021,2,17]],"date-time":"2021-02-17T00:00:00Z","timestamp":1613520000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,2,17]],"date-time":"2021-02-17T00:00:00Z","timestamp":1613520000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Microbiol Infect Dis"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1007\/s10096-021-04197-3","type":"journal-article","created":{"date-parts":[[2021,2,19]],"date-time":"2021-02-19T12:04:46Z","timestamp":1613736286000},"page":"1755-1759","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":58,"title":["Ceftazidime-avibactam, meropenen-vaborbactam, and imipenem-relebactam in combination with aztreonam against multidrug-resistant, metallo-\u03b2-lactamase-producing Klebsiella pneumoniae"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8553-0849","authenticated-orcid":false,"given":"Sofia","family":"Maraki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viktoria Eirini","family":"Mavromanolaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagiotis","family":"Moraitis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitra","family":"Stafylaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Kasimati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni","family":"Magkafouraki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Effie","family":"Scoulica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,17]]},"reference":[{"issue":"9","key":"4197_CR1","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/S1473-3099(13)70190-7","volume":"3","author":"LS Munoz-Price","year":"2013","unstructured":"Munoz-Price LS, Poirel L, Bonomo RA, Schwaber MJ, Daikos GL, Cormican M, Cornaglia G, Garau J, Gniadkowski M, Hayden MK, Kumarasamy K, Livermore DM, Maya JJ, Nordmann P, Patel JB, Paterson DL, Pitout J, Villegas MV, Wang H, Woodford N, Quinn JP (2013) Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases. Lancet Infect Dis 3(9):785\u2013796","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"4197_CR2","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.ajic.2016.08.008","volume":"45","author":"W Wang","year":"2017","unstructured":"Wang W, Jiang T, Zhang W, Li C, Chen J, Xiang D, Cao K, Qi LW, Li P, Zhu W, Chen W, Chen Y (2017) Predictors of mortality in bloodstream infections caused by multidrug-resistant gram-negative bacteria: 4 years of collection. Am J Infect Control 45(1):59\u201364","journal-title":"Am J Infect Control"},{"issue":"3","key":"4197_CR3","doi-asserted-by":"publisher","first-page":"e01709","DOI":"10.1128\/AAC.01709-16","volume":"61","author":"JT Thaden","year":"2017","unstructured":"Thaden JT, Li Y, Ruffin F, Maskarinec SA, Hill-Rorie JM, Wanda LC, Reed SD, Fowler VG Jr (2017) Increased costs associated with bloodstream infections caused by multidrug-resistant Gram-negative bacteria are due primarily to patients with hospital-acquired infections. Antimicrob Agents Chemother 61(3):e01709\u201316","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"4197_CR4","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.cmi.2016.01.023","volume":"22","author":"C Hauck","year":"2016","unstructured":"Hauck C, Cober E, Richter SS, Perez F, Salata RA, Kalayjian RC, Watkins RR, Scalera NM, Doi Y, Kaye KS, Evans S, Fowler VG Jr, Bonomo RA, van Duin D, Antibacterial Resistance Leadership Group (2016) Spectrum of excess mortality due to carbapenem-resistant Klebsiella pneumoniae infections. Clin Microbiol Infect 22(6):513\u2013519","journal-title":"Clin Microbiol Infect"},{"key":"4197_CR5","unstructured":"European Centre for Disease Prevention and Control (2019) Surveillance of antimicrobial resistance in Europe-annual report of the European Antimicrobial Resistance Surveillance Network (EARS-Net). https:\/\/www.ecdc.europa.eu\/en\/publications-data\/surveillance-antimicrobial-resistance-europe-2019.pdf"},{"issue":"2","key":"4197_CR6","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.ijantimicag.2017.03.030","volume":"50","author":"B Davido","year":"2017","unstructured":"Davido B, Bouchand F, Dinh A, Perronne C, Villart M, Senard O, Salomon J (2017) Reinforcement of an antimicrobial stewardship task force aims at a better use of antibiotics of last resort: the COLITIFOS study. Int J Antimicrob Agents 50(2):142\u2013147","journal-title":"Int J Antimicrob Agents"},{"key":"4197_CR7","doi-asserted-by":"crossref","unstructured":"Dickstein Y, Lellouche J, Schwartz D, Nutman A, Rakovitsky N, Dishon Benattar Y, Altunin S, Bernardo M, Iossa D, Durante-Mangoni E, Antoniadou A, Skiada A, Deliolanis I, Daikos GL, Daitch V, Yahav D, Leibovici L, Rogn\u00e5s V, Friberg LE, Mouton JW, Paul M, Carmeli Y; AIDA study group (2019) Colistin resistance development following colistin-meropenem combination therapy vs. colistin monotherapy in patients with infections caused by carbapenem-resistant organisms. Clin Infect Dis ciz1146","DOI":"10.1093\/cid\/ciz1146"},{"issue":"4","key":"4197_CR8","doi-asserted-by":"publisher","first-page":"e0175140","DOI":"10.1371\/journal.pone.0175140","volume":"12","author":"SK Chiu","year":"2017","unstructured":"Chiu SK, Chan MC, Huang LY, Lin YT, Lin JC, Lu PL, Siu LK, Chang FY, Yeh KM (2017) Tigecycline resistance among carbapenem-resistant Klebsiella pneumoniae: clinical characteristics and expression levels of efflux pump genes. PLoS One 12(4):e0175140","journal-title":"PLoS One"},{"issue":"Suppl 7","key":"4197_CR9","doi-asserted-by":"publisher","first-page":"S565","DOI":"10.1093\/cid\/ciz830","volume":"69","author":"Y Doi","year":"2019","unstructured":"Doi Y (2019) Treatment options for carbapenem-resistant gram-negative bacterial infections. Clin Infect Dis 69(Suppl 7):S565\u2013S575","journal-title":"Clin Infect Dis"},{"issue":"3","key":"4197_CR10","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","volume":"18","author":"AP Magiorakos","year":"2012","unstructured":"Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, Harbarth S, Hindler JF, Kahlmeter G, Olsson-Liljequist B, Paterson DL, Rice LB, Stelling J, Struelens MJ, Vatopoulos A, Weber JT, Monnet DL (2012) Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 18(3):268\u2013281","journal-title":"Clin Microbiol Infect"},{"issue":"1","key":"4197_CR11","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.diagmicrobio.2010.12.002","volume":"70","author":"L Poirel","year":"2011","unstructured":"Poirel L, Walsh TR, Cuvillier V, Nordmann P (2011) Multiplex PCR for detection of acquired carbapenemase genes. Diagn Microbiol Infect Dis 70(1):119\u2013123","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"5","key":"4197_CR12","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1007\/s10096-011-1360-5","volume":"31","author":"G Samonis","year":"2012","unstructured":"Samonis G, Maraki S, Karageorgopoulos DE, Vouloumanou EK, Falagas ME (2012) Synergy of fosfomycin with carbapenems, colistin, netilmicin, and tigecycline against multidrug-resistant Klebsiella pneumoniae, Escherichia coli, and Pseudomonas aeruginosa clinical isolates. Eur J Clin Microbiol Infect Dis 31(5):695\u2013701","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"4197_CR13","doi-asserted-by":"crossref","unstructured":"Galani I, Karaiskos I, Karantani I, Papoutsaki V, Maraki S, Papaioannou V, Kazila P, Tsorlini H, Charalampaki N, Toutouza M, Vagiakou H, Pappas K, Kyratsa A, Kontopoulou K, Legga O, Petinaki E, Papadogeorgaki H, Chinou E, Souli M, Giamarellou H, On Behalf Of The Study Collaborators (2018) Epidemiology and resistance phenotypes of carbapenemase-producing Klebsiella pneumoniae in Greece, 2014 to 2016. Euro Surveill 23(31)","DOI":"10.2807\/1560-7917.ES.2018.23.30.1700775"},{"issue":"3","key":"4197_CR14","first-page":"136","volume":"43","author":"F Romanelli","year":"2020","unstructured":"Romanelli F, De Robertis A, Carone G, Dalfino L, Stufano M, Del Prete R, Mosca A (2020) In vitro activity of ceftazidime\/avibactam alone and in combination with fosfomycin and carbapenems against KPC-producing Klebsiella pneumoniae. New Microbiol 43(3):136\u2013138","journal-title":"New Microbiol"},{"issue":"5","key":"4197_CR15","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1016\/j.ijantimicag.2018.07.011","volume":"52","author":"LM Avery","year":"2018","unstructured":"Avery LM, Nicolau DP (2018) Assessing the in vitro activity of ceftazidime\/avibactam and aztreonam among carbapenemase-producing Enterobacteriaceae: defining the zone of hope. Int J Antimicrob Agents 52(5):688\u2013691","journal-title":"Int J Antimicrob Agents"},{"issue":"2","key":"4197_CR16","doi-asserted-by":"publisher","first-page":"105863","DOI":"10.1016\/j.ijantimicag.2019.105863","volume":"55","author":"LM Avery","year":"2020","unstructured":"Avery LM, Mullane EM, Nicolau DP (2020) Evaluation of the in vitro activity of WCK 5222 (cefepime\/zidebactam) and currently available combination therapies against single- and double-carbapenemase producing Enterobacteriaceae: expanding the zone of hope. Int J Antimicrob Agents 55(2):105863","journal-title":"Int J Antimicrob Agents"},{"issue":"4","key":"4197_CR17","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.diagmicrobio.2017.05.009","volume":"88","author":"E Wenzler","year":"2017","unstructured":"Wenzler E, Deraedt MF, Harrington AT, Danizger LH (2017) Synergistic activity of ceftazidime-avibactam against serine and metallo-\u03b2-lactamase producing Gram-negative pathogens. Diagn Microbiol Infect Dis 88(4):352\u2013354","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"2","key":"4197_CR18","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1093\/jac\/dkx393","volume":"73","author":"A Jayol","year":"2018","unstructured":"Jayol A, Nordmann P, Poirel L, Dubois V (2018) Ceftazidime\/avibactam alone or in combination with aztreonam against colistin-resistant and carbapenemase-producing Klebsiella pneumoniae. J Antimicrob Chemother 73(2):542\u2013544","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"4197_CR19","doi-asserted-by":"publisher","first-page":"e02243","DOI":"10.1128\/AAC.02243-16","volume":"61","author":"S Marshall","year":"2017","unstructured":"Marshall S, Hujer AM, Rojas LJ, Papp-Wallace KM, Humphries RM, Spellberg B, Hujer KM, Marshall EK, Rudin SD, Perez F, Wilson BM, Wasserman RB, Chikowski L, Paterson DL, Vila AJ, van Duin D, Kreiswirth BN, Chambers HF, Fowler VG Jr, Jacobs MR, Pulse ME, Weiss WJ, Bonomo RA (2017) Can ceftazidime-avibactam overcome \u03b2-lactam resistance conferred by metallo-\u03b2-lactamases in Enterobacteriaceae? Antimicrob Agents Chemother 61(4):e02243\u201316","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"4197_CR20","doi-asserted-by":"publisher","first-page":"34","DOI":"10.4103\/ijmm.IJMM_19_189","volume":"37","author":"AK Pragasam","year":"2019","unstructured":"Pragasam AK, Veeraraghavan B, Shankar BA, Bakthavatchalam YD, Mathuram A, George B, Chacko B, Korula P, Anandan S (2019) Will ceftazidime\/avibactam plus aztreonam be effective for NDM and OXA-48-like producing organisms. Lessons learnt for in vitro study. Indian J Med Microbiol 37(1):34\u201341","journal-title":"Indian J Med Microbiol"},{"issue":"12","key":"4197_CR21","first-page":"e01426","volume":"63","author":"M Biagi","year":"2019","unstructured":"Biagi M, Wu T, Lee M, Patel S, Butler D, Wenzler E (2019) Searching for the optimal treatment for metallo- and serine-\u03b2-lactamase-producing Enterobacteriaceae: aztreonam in combination with ceftazidime-avibactam or meropenem-vaborbactam. Antimicrob Agents Chemother 63(12):e01426\u201319","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"4197_CR22","doi-asserted-by":"publisher","first-page":"e01008","DOI":"10.1128\/AAC.01008-17","volume":"61","author":"B Davido","year":"2017","unstructured":"Davido B, Fellous L, Lawrence C, Maxime V, Rottman M, Dinh A (2017) Ceftazidime-avibactam and aztreonam, an interesting strategy to overcome \u03b2-lactam resistance conferred by metallo-\u03b2-lactamases in Enterobacteriaceae and Pseudomonas aeruginosa. Antimicrob Agents Chemother 61(9):e01008\u201317","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"4197_CR23","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1093\/cid\/ciz1155","volume":"71","author":"M Yasmin","year":"2020","unstructured":"Yasmin M, Fouts DE, Jacobs MR, Haydar H, Marshall SH, White R, D\u2019Souza R, Lodise TP, Rhoads DD, Hujer AM, Rojas LJ, Hoyen C, Perez F, Edwards A, Bonomo RA (2020) Monitoring ceftazidime-avibactam and aztreonam concentrations in the treatment of a bloodstream infection caused by a multidrug-resistant Enterobacter sp. carrying both Klebsiella pneumoniae carbapenemase-4 and New Delhi metallo-\u03b2-lactamase-1. Clin Infect Dis 71(4):1095\u20131098","journal-title":"Clin Infect Dis"},{"issue":"2","key":"4197_CR24","doi-asserted-by":"publisher","first-page":"e02463","DOI":"10.1128\/AAC.02463-18","volume":"63","author":"CA Hobson","year":"2019","unstructured":"Hobson CA, Bonacorsi S, Fahd M, Baruchel A, Cointe A, Poey N, Jacquier H, Doit C, Monjault A, Tenaillon O, Birgy A (2019) Successful treatment of bacteremia due to NDM-1-producing Morganella morganii with aztreonam and ceftazidime-avibactam combination in a pediatric patient with hematologic malignancy. Antimicrob Agents Chemother 63(2):e02463\u201318","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"4197_CR25","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1093\/jac\/dkx496","volume":"73","author":"E Shaw","year":"2018","unstructured":"Shaw E, Rombauts A, Tubau F, Padull\u00e9s A, C\u00e0mara J, Lozano T, Cobo-Sacrist\u00e1n S, Sabe N, Grau I, Rigo-Bonnin R, Dominguez MA, Carratal\u00e0 J (2018) Clinical outcomes after combination treatment with ceftazidime\/avibactam and aztreonam for NDM-1\/OXA-48\/CTX-M-15-producing Klebsiella pneumoniae infection. J Antimicrob Chemother 73(4):1104\u20131106","journal-title":"J Antimicrob Chemother"},{"key":"4197_CR26","doi-asserted-by":"crossref","unstructured":"Falcone M, Gaikos GL, Tiseo G, Bassoulis D, Giordano C, Galfo V, Leonildi A, Tagliaferri E, Barnini S, Sani S, Farcomeni A, Ghiadoni L, Menichetti F (2020) Efficacy of ceftazidime-avibactam plus aztreonam in patients with bloodstream infections caused by MBL- producing Enterobacterales. Clin Infect Dis ciaa586.","DOI":"10.1093\/cid\/ciaa586"},{"key":"4197_CR27","doi-asserted-by":"crossref","unstructured":"Karlowsky JA, Kazmierczak KM, de Jonge BLM, Hackel MA, Sahm DF, Bradford PA (2017) In vitro activity of aztreonam-avibactam against Enterobacteriaceae and Pseudomonas aeruginosa isolated by clinical laboratories in 40 countries from 2012 to 2015. Antimicrob Agents Chemother 61(9):e00472\u201317","DOI":"10.1128\/AAC.00472-17"},{"issue":"1","key":"4197_CR28","first-page":"e01856","volume":"62","author":"HS Sader","year":"2017","unstructured":"Sader HS, Mendes RE, Pfaller MA, Shortridge D, Flamm RK, Castanheira M (2017) Antimicrobial activities of aztreonam-avibactam and comparator agents against contemporary (2016) clinical Enterobacteriaceae isolates. Antimicrob Agents Chemother 62(1):e01856\u201317","journal-title":"Antimicrob Agents Chemother"},{"key":"4197_CR29","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ijid.2020.05.075","volume":"97","author":"B Zhang","year":"2020","unstructured":"Zhang B, Zhu Z, Jia W, Qu F, Huang B, Shan B, Yu H, Tang Y, Chen L, Du H (2020) In vitro activity of aztreonam-avibactam against metallo-\u03b2-lactamase-producing Enterobacteriaceae- a multicenter study in China. Int J Infect Dis 97:11\u201318","journal-title":"Int J Infect Dis"},{"issue":"3","key":"4197_CR30","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1093\/jac\/dkz497","volume":"75","author":"OA Cornely","year":"2020","unstructured":"Cornely OA, Cisneros JM, Torre-Cisneros J, Rodr\u00edguez-Hern\u00e1ndez MJ, Tall\u00f3n-Aguilar L, Calbo E, Horcajada JP, Queckenberg C, Zettelmeyer U, Arenz D, Rosso-Fern\u00e1ndez CM, Jim\u00e9nez-Jorge S, Turner G, Raber S, O\u2019Brien S, Luckey A, COMBACTE-CARE consortium\/REJUVENATE Study Group (2020) Pharmacokinetics and safety of aztreonam\/avibactam for the treatment of complicated intra-abdominal infections in hospitalized adults: results from the REJUVENATE study. J Antimicrob Chemother 75(3):618\u2013627","journal-title":"J Antimicrob Chemother"},{"issue":"7","key":"4197_CR31","doi-asserted-by":"publisher","first-page":"e00486","DOI":"10.1128\/AAC.00486-17","volume":"61","author":"ML Monogue","year":"2017","unstructured":"Monogue ML, Abbo LM, Rosa R, Camargo JF, Martinez O, Bonomo RA, Nicolau DP (2017) In vitro discordance with in vivo activity: humanized exposures of ceftazidime-avibactam, aztreonam, and tigecycline alone and in combination against New Delhi metallo-\u03b2-lactamase-producing Klebsiella pneumoniae in a murine lung infection model. Antimicrob Agents Chemother 61(7):e00486\u201317","journal-title":"Antimicrob Agents Chemother"}],"container-title":["European Journal of Clinical Microbiology & Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-021-04197-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10096-021-04197-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-021-04197-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,21]],"date-time":"2021-07-21T14:45:35Z","timestamp":1626878735000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10096-021-04197-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,17]]},"references-count":31,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["4197"],"URL":"https:\/\/doi.org\/10.1007\/s10096-021-04197-3","relation":{},"ISSN":["0934-9723","1435-4373"],"issn-type":[{"value":"0934-9723","type":"print"},{"value":"1435-4373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,17]]},"assertion":[{"value":"14 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was waived by the local Ethics Committee of the University Hospital of Heraklion in view of the retrospective nature of the study and all the procedures being performed were part of the routine care.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All authors have read the manuscript and approved submission.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}